NCT06687759View on ClinicalTrials.gov

A Study of MK-1084 Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

June 26, 2024

Primary Completion Date

August 7, 2024

Study Completion Date

August 7, 2024

Conditions

Healthy

Interventions

DRUG

[14C]MK-1084

Oral administration

Trial Locations (1)

53704

Fortea CRU Madison (Site 0001), Madison

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY